# THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

#### SUPER NOVA PETROLEUM CORP.

CSE (CNSX): SNP OTC: SNOVF

#### **NEWS RELEASE**

## SUPER NOVA ANNOUNCES EXERCISE OF OVER ALLOTMENT OPTION AND CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT

Vancouver, BC, November 30, 2017 - Super Nova Petroleum Corp. (CSE/CSNX: SNP; OTC: SNOVF) (the "Company" or "Super Nova") announces that, further to the news releases dated September 29, October 23, 2017 and October 30, 2017, the Company has closed the second tranche of its \$2 million non-brokered private placement. The second tranche consisted of the sale of 1,750,000 subscription receipts (each, a "Subscription Receipt") for gross proceeds of \$350,000. In the event that the Company completes the purchase of Koios, LLC ("Koios") (the 'Transaction") on or before January 31, 2018, each Subscription Receipt will be automatically converted, for no additional consideration, into one common share (each, a "Share") of the Company. The Company has agreed to pay an aggregate of \$14,100 in finders' fees in connection with the second tranche. The Company has raised a total of \$2,295,000 from the closing of the first and second tranches of the Financing.

The Company exercised its overallotment option and is expecting to close a third tranche of the private placement for gross proceeds of up to an additional \$105,000.

On release from escrow, the net proceeds from the financing will allow Koios to start producing next generation products, through advanced research and development. Koios intends on expanding its product line to meet consumer demand and to be more competitive on store shelves and intends on expanding its current sales force to capitalize on retail growth and drive bottom line revenue. Koios also intends on expanding its digital presence through increased marketing and progressive ecommerce strategies.

Each Share issued upon conversion of the Subscription Receipt will be subject to a hold period expiring four months and one day after the closing of each tranche of the private placement.

### Conditions of the Transaction

Completion of the Transaction remains subject to, among other things, satisfactory due diligence by the parties, approval of the CSE, completion of the financing, approval of the shareholders of the Company and other conditions which are customary for transactions of this nature.

### **About Koios**

Koios in an emerging functional beverage company whose products are currently available in over 2,000 retail locations across the country. Koios has relationships with some of the largest

and most reputable distributors in the country; Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well. Together these distributors represent over 80,000 brick and mortar locations across the United States from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets. Through our partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.

Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.

Koios enhances focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and creates all day mental clarity. Our ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.

Koios is one of the only drinks in the world to infuse its products with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, creates lasting energy from a natural food source, produces ketones in the brain, allowing for greater brain function and clarity, supports healthy hormone production and improves immunity.

On behalf of the Board of Directors of the Company.

### SUPER NOVA PETROLEUM CORP.

"Wolf Wiese"
Wolf Wiese
CEO

For further information, please contact:

Corporate Communications 604-221-8936

Completion of the Transaction is subject to a number of conditions, including CSE acceptance. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Super Nova should be considered highly speculative.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this news release.

## Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: the closing of the Transaction; the closing of the third tranche of the private placement and the expected use of proceeds thereof. The forward-looking statements reflect management's current expectations based on

information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements.

Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include, among other things: that the CSE or the Company's shareholders may not approve the Transaction as proposed or at all; that the parties may not be able to satisfy the conditions to closing of the Transaction; that the Company may not be able to complete the third tranche of the private placement; general market conditions; and other factors beyond the control of the parties. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Koios has not conducted any scientific studies on the effects of Koios' products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios' products will vary from person to person. No claims or guarantees can be made as to the effects of Koios' products on an individual's health and wellbeing.